{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003945","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.783380+00:00","generated_at":"2026-06-07T02:18:42.514534+00:00","sec_items":["2.05","5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atara cuts 25% of workforce, restructures to focus on CAR-T; CMO departs","bullets":["Workforce reduction of ~25% (approx. 56 employees) expected to complete by May 2024; severance costs ~$4.5M.","CMO Manher Joshi to depart Feb 2, 2024; receives 12 months severance, $3k/month consulting fee, $185k tab-cel BLA milestone.","Restructuring plus $27M upfront from Pierre Fabre pact and existing cash expected to fund operations into 2027.","Tab-cel BLA on track for Q2 2024 submission; pivotal ALLELE study showed ORR 49% (p<0.0001).","IND for ATA3219 in Lupus Nephritis planned Q1 2024; preliminary clinical data in lymphoma expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003945","json":"https://secwatch.observer/filing/0001193125-24-003945.json","markdown":"https://secwatch.observer/filing/0001193125-24-003945.md","text":"https://secwatch.observer/filing/0001193125-24-003945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524003945/0001193125-24-003945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524003945/d703405d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:18:42.514534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5326b81e44","claim":"Manher (AJ) Joshi was terminated as Executive Vice President, Chief Medical Officer at Atara Biotherapeutics, Inc..","evidence_excerpt":"On January 8, 2024, the Company announced that the employment of Manher (AJ) Joshi, the Company’s Executive Vice President, Chief Medical Officer, would terminate effective as of February 2, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524003945/0001193125-24-003945-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Executive Vice President, Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"4b16d5a773c25fdea33e83afea855f8d59a36494","claim":"Atara Biotherapeutics, Inc. announced a restructuring with charges of approximately $4.5 million (approximately 25% of its current employees).","evidence_excerpt":"On January 8, 2024, Atara Biotherapeutics, Inc. (the “Company”) announced a reduction in its workforce that will impact approximately 25% of its current employees. The Company expects to substantially complete the workforce reduction by May 2024. The Company expects to recognize approximately $4.5 million in total for severance and related benefits for employees laid off under the reduction in force.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524003945/0001193125-24-003945-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $4.5 million"},{"label":"Headcount","value":"approximately 25% of its current employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}